Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can Sanofi’s Toujeo Prickle Tresiba In India?

Executive Summary

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

You may also be interested in...



Novo Nordisk’s New India Chief Steps Into Bustling Diabetes Arena

Novo Nordisk’s new India managing director takes charge amid heightened competition in the diabetes space. The Danish firm stays committed to bringing new products to this market at a faster clip and all eyes will be on the launch trajectory of therapies like semaglutide.

Biocon To Buttress India Market Glargine Supply From Malaysia Site

Biocon expects to meet Indian requirements for its insulin glargine with supplies from both home and abroad. It plans to import the product from its Malaysian site and will need to do Phase IV studies in Indian patients, but underscores that no price increase is likely for the imported version to ensure affordable access.

Can ‘Long-Term Partner’ Cipla Breathe New Life Into MannKind’s Afrezza?

Cipla is to commercialize the financially troubled MannKind’s inhaled insulin Afrezza in India, but it remains to be seen whether the deal can materially change the fortunes of the product.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel